On October 2, 2023, Grégory Behar informed Seres Therapeutics, Inc. (the ?Company?) of his resignation from the board of directors of the Company, effective immediately, in connection with his resignation from Nestlé Health Science.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9199 USD | -0.49% | -9.81% | -34.29% |
09/05 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
09/05 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.29% | 140M | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Grégory Behar Resigns from Board of Directors of Seres Therapeutics, Inc